If you have registered for this members-only webinar, you should have received an email with details of how to join the meeting. If not, or you have not rsvp’d please sign in to access details.
Could the next-generation of Covid-19 vaccines come in pill form?
Join the latest MJA webinar, at 6pm on June 14 to learn more on a range of oral recombinant vaccines being developed by the US-based biotech company Vaxart — whose pipeline includes oral vaccines for Norovirus, RSV and Covid-19.
Hosted by MJA Chair Nigel Praities, the online meeting will preview the latest news on Vaxart’s oral COVID-19 vaccine — and the science which suggests oral delivery might provide a stronger immune response than traditional injections, and overcome some of the challenges around the need to store current recombinant vaccines at low temperatures.
The webinar, which has been organised exclusively for MJA members, will also explore how this new technology might reduce vaccine hesitancy and boost vaccination rates across the world. Members will also have the opportunity to put questions to the panel:
- Andrei Floroiu, president and CEO, Vaxart
- Dr Sean Tucker, chief scientific officer, Vaxart
- Dr James Cummings, chief medical officer, Vaxart
- Brant Biehn, senior VP business operations, Vaxart
Date and time: 14 June, 6-7pm
Location: Zoom meeting — please RSVP below to confirm your attendance, sign in details will be forwarded shortly before the event.
Visit the Vaxart website for more information on the company — who are sponsoring this year’s MJA Award for News Story of the Year (General Audience).